Decreased Plaque Formation Research Articles

Comparative anti-plaque and anti-gingivitis efficiency of Triphala versus chlorhexidine mouthwashes in children: a systematic review and meta-analysis.

The aim of this systematic review is to comparatively evaluate the Triphala and chlorhexidine mouthwashes efficacies in decreasing plaque formation and gingivitis in children. With a priori-set inclusion and exclusion criteria's and relevant MeSH terms, the PubMed, Cochrane and Ovid SP were scrutinized from the year 1980 to April 2023 for prospective articles. Outcomes evaluated were plaque formation and gingivitis through Plaque index and Gingival index. Five studies were finally included and were analyzed qualitatively and quantitatively. Meta-analysis, was performed using a random effects model. Plaque index (PI) and Gingival Index (GI). There was no significant difference between reduction in the gingivitis and plaque accumulation between Triphala and chlorhexidine mouthwash groups in children (p value 0.83, 0.96).

α-Tocopherol inhibits atherogenesis and improves cardiac function in mice independently of its antioxidant properties.

The impact of α-tocopherol on atherosclerosis is unclear and controversial. While some studies suggest potential benefits, such as antioxidant properties that may reduce oxidative stress, other studies indicate no significant preventive effects. The intricate interplay of various factors, including dosage, individual differences, and study methodologies, contributes to the ongoing uncertainty surrounding α-tocopherol's role in atherosclerosis. Further research is needed to clarify its impact and establish clearer guidelines. Therefore, we aimed to evaluate the impact of α-tocopherol on atherogenesis in ApoE-/- fibrillin (Fbn)1C1039G/+ mice, which is a unique mouse model of advanced atherosclerosis with typical features, such as large necrotic cores, high levels of inflammation, and intraplaque neovascularization, that resemble the unstable phenotype of human plaques. ApoE-/- Fbn1C1039G+/- mice were fed a western-type diet (WD) supplemented with a high dose of α-tocopherol (500 mg/kg diet), while control mice were fed a WD containing a low dose of α-tocopherol (50 mg/kg diet). The high dose of α-tocopherol reduced plaque thickness and necrotic core area in the right common carotid artery (RCCA) after 24 weeks WD. Moreover, α-tocopherol decreased plaque formation and intraplaque neovascularization in the RCCA. In addition to its antiatherogenic effect, chronic supplementation of α-tocopherol improved cardiac function in ApoE-/- Fbn1C1039G/+ mice. However, chronic supplementation of α-tocopherol did not decrease lipid peroxidation. On the contrary, α-tocopherol acted as a prooxidant by increasing plasma levels of oxidized LDL and plaque malondialdehyde, an end product of lipid peroxidation. Our data indicate that α-tocopherol inhibits atherogenesis and improves cardiac function independent of its antioxidant properties.

Abstract 3131: An Investigation Into The Interplay Between Epha2 And Inflammatory Responses In Vascular Smooth Muscle Cells

Cardiovascular disease continues to be a leading cause of death in the United States. A major underlying cause of cardiovascular events such as stroke and myocardial infarction is atherosclerosis. Notable mediators in the pathogenesis of atherosclerosis include vascular smooth muscle cells (VSMCs) and inflammation. During atherogenesis, the SMCs undergo phenotypic change from a quiescent state to a synthetic, proliferative state. The synthetic SMCs drive neointima formation which influences the stenosis characteristic of atherosclerosis. Signaling of a receptor tyrosine kinase called EphA2 has been previously determined to have a role in SMC phenotypic change. It was found that a global and SMC specific knockdown (KD) of EphA2 resulted in decreased plaque formation, suggesting the role of EphA2 expression in promoting SMC proliferation. Inflammation is another important factor that contributes to plaque formation. Oxidized low-density lipoproteins (LDLs) have been found to also cause VSMCs to undergo change to a synthetic phenotype, one that resembles macrophages. Cytokines released by macrophages orchestrate the pro-inflammatory response that affects the development and stability of atherosclerotic plaques. Considering the important role inflammation also serves in the progression of plaque formation, we investigated the relationship between EphA2 and VSMC-mediated inflammatory response. Cre-flox breeding was performed to achieve EphA2 knockout (KO) specifically in VSMCs of 8-10-wk old ApoE -/- mice. Successful KO was confirmed with PCR and Western blot. Si-RNA was transfected to achieve KD in human SMCs. The cells were then treated with cytokines, including IL-1 beta, TNF-alpha, IL-6, IL-33, and interferon-gamma, followed by RT-qPCR analysis to measure expression of inflammatory genes. To assess cytokine secretion, we utilized a cytokine array to measure presence of the cytokines of interest. Protein analysis to quantify expression of inflammatory proteins in KO vs control cells was done via Western blot. We observed that the loss of EphA2 causes significant reductions in the production of several proinflammatory cytokines and chemokines, indicating its role in mediating VSMC inflammatory responses.

Myeloid PHD2 Conditional Knockout Improves Intraplaque Angiogenesis and Vascular Remodeling in a Murine Model of Venous Bypass Grafting.

Intraplaque angiogenesis occurs in response to atherosclerotic plaque hypoxia, which is driven mainly by highly metabolically active macrophages. Improving plaque oxygenation by increasing macrophage hypoxic signaling, thus stimulating intraplaque angiogenesis, could restore cellular function and neovessel maturation, and decrease plaque formation. Prolyl hydroxylases (PHDs) regulate cellular responses to hypoxia. We therefore aimed to elucidate the role of myeloid PHD2, the dominant PHD isoform, on intraplaque angiogenesis in a murine model for venous bypass grafting. Myeloid PHD2 conditional knockout (PHD2cko) and PHD2 wild type mice on an Ldlr-/- background underwent vein graft surgery (n=11-15/group) by interpositioning donor caval veins into the carotid artery of genotype-matched mice. At postoperative day 28, vein grafts were harvested for morphometric and compositional analysis, and blood was collected for flow cytometry. Myeloid PHD2cko induced and improved intraplaque angiogenesis by improving neovessel maturation, which reduced intraplaque hemorrhage. Intima/media ratio was decreased in myeloid PHD2cko vein grafts. In addition, PHD2 deficiency prevented dissection of vein grafts and resulted in an increase in vessel wall collagen content. Moreover, the macrophage proinflammatory phenotype in the vein graft wall was attenuated in myeloid PHD2cko mice. Invitro cultured PHD2cko bone marrow-derived macrophages exhibited an increased proangiogenic phenotype compared with control. Myeloid PHD2cko reduces vein graft disease and ameliorates vein graft lesion stability by improving intraplaque angiogenesis.

Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways.

Macrophage-derived foam cells play a causal role during the pathogenesis of atherosclerosis. P2Y6 receptor (P2Y6R) highly expressed has been considered as a disease-causing factor in atherogenesis, but the detailed mechanism remains unknown. This study aims to explore P2Y6R in regulation of macrophage foaming, atherogenesis, and its downstream pathways. Furthermore, the present study sought to find a potent P2Y6R antagonist and investigate the feasibility of P2Y6R-targeting therapy for atherosclerosis. The P2Y6R expression was examined in human atherosclerotic plaques and mouse artery. Atherosclerosis animal models were established in whole-body P2Y6R or macrophage-specific P2Y6R knockout mice to evaluate the role of P2Y6R. RNA sequencing, DNA pull-down experiments, and proteomic approaches were performed to investigate the downstream mechanisms. High-throughput Glide docking pipeline from repurposing drug library was performed to find potent P2Y6R antagonists. The P2Y6R deficiency alleviated atherogenesis characterized by decreasing plaque formation and lipid deposition of the aorta. Mechanically, deletion of macrophage P2Y6R significantly inhibited uptake of oxidized low-density lipoprotein through decreasing scavenger receptor A expression mediated by phospholipase Cβ/store-operated calcium entry pathways. More importantly, P2Y6R deficiency reduced the binding of scavenger receptor A to CALR, accompanied by dissociation of calreticulin and STIM1. Interestingly, thiamine pyrophosphate was found as a potent P2Y6R antagonist with excellent P2Y6R antagonistic activity and binding affinity, of which the pharmacodynamic effect and mechanism on atherosclerosis were verified. Macrophage P2Y6R regulates phospholipase Cβ/store-operated calcium entry/calreticulin signalling pathway to increase scavenger receptor A protein level, thereby improving foam cell formation and atherosclerosis, indicating that the P2Y6R may be a potential therapeutic target for intervention of atherosclerotic diseases using P2Y6R antagonists including thiamine pyrophosphate.

Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism

ObjectiveAtherosclerosis is a chronic inflammatory process induced by the influx and entrapment of excess lipoproteins into the intima media of arteries. Previously, our lab demonstrated that systemic PTP1B inhibition protects against atherosclerosis in preclinical LDLR−/− models. Similarly, it was shown that myeloid-specific PTP1B ablation decreases plaque formation and ameliorates dyslipidaemia in the ApoE−/− model of atherosclerosis. We hypothesized that the relevant improvements in dyslipidaemia following modification of PTP1B activation may either result from changes in hepatic cholesterol biosynthesis and/or increased uptake and degradation by liver-resident macrophages. We examined this in animal models and patients with coronary artery disease.MethodsIn this study, we determined the cholesterol-lowering effect of myeloid-PTP1B deletion in mice fed a high-fat high-cholesterol diet and examined effects on total cholesterol levels and lipoprotein profiles. We also determined the effects of PTP1B inhibition to oxLDL-C challenge on foam cell formation and cholesterol efflux in human monocytes/macrophages.ResultsWe present evidence that myeloid-PTP1B deficiency significantly increases the affinity of Kupffer cells for ApoB containing lipoproteins, in an IL10-dependent manner. We also demonstrate that PTP1B inhibitor, MSI-1436, treatment decreased foam cell formation in Thp1-derived macrophages and increased macrophage cholesterol efflux to HDL in an AMPK-dependent manner. We present evidence of three novel and distinct mechanisms regulated by PTP1B: an increase in cholesterol efflux from foam cells, decreased uptake of lipoproteins into intra-lesion macrophages in vitro and a decrease of circulating LDL-C and VLDL-C in vivo.ConclusionsOverall, these results suggest that myeloid-PTP1B inhibition has atheroprotective effects through improved cholesterol handling in atherosclerotic lesions, as well as increased reverse cholesterol transport.Trial registration Research registry, researchregistry 3235. Registered 07 November 2017, https://www.researchregistry.com/browse-the-registry#home/registrationdetails/5a01d0fce7e1904e93e0aac5/.

A Comparative Evaluation of Flax Seed and Coconut Oil Pulling Therapy on Plaque-Induced Gingivitis: A Preliminary Report

Oil pulling is a traditional shown promising result in controlling bleeding and reducing inflammation of periodontium. Hence, the present study was aimed to compare and evaluate the efficacy of flax seed and coconut oil as an anti-inflammatory agent with chlorhexidine gluconate in the treatment of plaque-induced gingivitis. The randomized controlled clinical trial involved 45 participants divided into three groups, each with 15 participants. Clinical parameters like Plaque index (PI), Gingival index (GI), Sulcular Bleeding Index (SBI) were assessed at baseline, 1 month, 3 months and 6 months. Statistical analysis was carried out using SPSS software 22.0. Results showed a significant decrease in pre- and post-treatment clinical parameters, indicating that flax seed and coconut oil pulling used as adjunctive oral hygiene aids were effectively decreased plaque formation and gingivitis.

Confounding Effects of Tamoxifen: Cautionary and Practical Considerations for the Use of Tamoxifen-Inducible Mouse Models in Atherosclerosis Research-Brief Report.

In recent years, fate-mapping lineage studies in mouse models have led to major advances in vascular biology by allowing investigators to track specific cell populations in vivo. One of the most frequently used lineage tracing approaches involves tamoxifen-inducible CreERT-LoxP systems. However, tamoxifen treatment can also promote effects independent of Cre recombinase activation, many of which have not been fully explored. To elucidate off-target effects of tamoxifen, male and female mice were either unmanipulated or injected with tamoxifen or corn oil. All mice received PCSK9 (proprotein convertase subtilisin/kexin type 9)-AAV (adeno-associated virus) injections and a modified Western diet to induce hypercholesterolemia. After 2 weeks, serum cholesterol and liver morphology were assessed. To determine the duration of any tamoxifen effects in long-term atherosclerosis experiments, mice received either 12 days of tamoxifen at baseline or 12 days plus 2 sets of 5-day tamoxifen boosters; all mice received PCSK9-AAV injections and a modified Western diet to induce hypercholesterolemia. After 24 weeks, serum cholesterol and aortic sinus plaque burden were measured. After 2 weeks of atherogenic treatment, mice injected with tamoxifen demonstrated significantly reduced serum cholesterol levels compared with uninjected- or corn oil-treated mice. However, there were no differences in PCSK9-mediated knockdown of LDL (low-density lipoprotein) receptors between the groups. Additionally, tamoxifen-treated mice exhibited significantly increased hepatic lipid accumulation compared with the other groups. Finally, the effects of tamoxifen remained for at least 8 weeks after completion of injections, with mice demonstrating persistent decreased serum cholesterol and impaired atherosclerotic plaque formation. In this study, we establish that tamoxifen administration results in decreased serum cholesterol, decreased plaque formation, and increased hepatic lipid accumulation. These alterations represent significant confounding variables in atherosclerosis research, and we urge future investigators to take these findings into consideration when planning and executing their own atherosclerosis experiments.

Comparative Study of Safety and Efficacy of Angiotensin-Receptor Blockers and Anti Amyloid-ß Monoclonal Antibodies for the Treatment of Alzheimer's Disease: A Systematic Review.

Amyloid-ß (Aß) plaques and Neurofibrillary tangles are hallmarks of Alzheimer's disease (AD) pathology. Recent advances to find a cure for AD have led to the exploration of Anti-Aß monoclonal antibodies and angiotensin-receptor blockers (ARBs). The antibodies can decrease plaque formation or remove already formed plaques. ARBs increase angiotensin II (AT2) levels and decrease the effect of AT2 on the AT1 receptor (AT1R). This systematic analysis reviews evidence of monoclonal antibodies (Aducanumab, Lecanemab, Donanemab, and Solanezumab) and ARBs in managing AD. An in-depth methodical search was conducted across PubMed, Science Direct, and Mendeley. PRISMA 2020 guidelines were followed for this study. Randomized control trials for antibodies and ARBs and one retrospective cohort study were included. The comparison was made among studies that shared similar measured outcomes. Antibodies were found to be more effective than ARBs, with Aducanumab and Lecanemab being the most effective. ARBs, on the other hand, were found to be the safer choice. Further trials of longer duration and larger sample sizes are needed to explore both groups' long-term safety and efficacy.

Reproductive and immune effects emerge at similar thresholds of PFHxS in deer mice

Although perfluorohexane sulfonate (PFHxS) is structurally similar to perfluorooctane sulfonate (PFOS) and also widely detected in humans and the environment, comparatively fewer toxicity data exists on this 6-chain perfluoroalkyl sulfonic acid. In this study, repeated oral doses of PFHxS were administered to deer mice (Peromyscus maniculatus) to evaluate subchronic toxicity and potential effects on reproduction and development. Maternal oral exposure to PFHxS caused increased stillbirths, which is relevant for ecological risk assessment, and resulted in a benchmark dose lower limit (BMDL) of 5.72 mg/kg-d PFHxS. Decreased plaque formation, which is relevant for human health risk assessment, occurred in both sexes of adult animals (BMDL = 8.79 mg/kg-d PFHxS). These data are the first to suggest a direct link between PFHxS and decreased functional immunity in an animal model. Additionally, female animals exhibited increased liver:body weight and animals of both sexes exhibited decreased serum thyroxine (T4) levels. Notably, since reproductive effects were used to support 2016 draft health advisories and immune effects were used in 2022 drinking water health advisories released by the United States Environmental Protection Agency for PFOS and perfluorooctanoic acid (PFOA), these novel data can potentially support advisories for PFHxS because relevant points of departure emerge at similar thresholds in a wild mammal and corroborate the general understanding of per- and polyfluoroalkyl substances (PFAS).

Tumor-Derived PD-L1+ Exosomes with Natural Inflammation Tropism for Psoriasis-Targeted Treatment.

Psoriasis is a chronic inflammatory disease whose etiology is directly related to the dysregulation of cutaneous immune homeostasis. However, how to finely modulate the skin immune microenvironment to restore homeostasis remains an important challenge. Inspired by the natural attribute of tumor exosomes in the immune escape, the tumor-derived exosomes as an active targeting nanoplatform for the effective treatment of inflammatory skin disorder were first reported. As keratinocytes and immune cells express high PD-1 during the onset of psoriasiform skin inflammation, the PD-L1-positive exosomes derived from melanoma cells carrying pristimerin with extremely anti-inflammatory potential were yielded to treat psoriasis. The PD-L1+ exosomes carrying pristimerin were characterized, and the cellular uptake was performed to evaluate the PD-1 target capability. The anti-inflammatory action of PD-L1+ exosomes carrying pristimerin was observed in both in vitro and in vivo models of psoriasis. Our exosomes substantially increased pristimerin uptake with CD4+ T cells and keratinocytes, significantly inhibited the proliferation of Th17 cells, and promoted Treg differentiation in a psoriasis-like model. Obviously, PD-L1+ exosomes carrying pristimerin significantly and safely reversed imiquimod (IMQ)-induced psoriasis in mice, indicated by reducing epidermal thickness, decreasing plaque formation, and suppressed excessive inflammatory response, due to its dual targeting of both CD4+ T cells and keratinocytes gathering around the lesion. The inflammatory cell infiltration and pro-inflammatory cytokine production in psoriasis were suppressed by our engineered exosomes. Besides, PD-L1+ exosomes carrying pristimerin treatment alleviated ferroptosis-related changes in psoriatic skin, thereby dampening excessive inflammation and, in turn, decreasing the abnormal proliferation of keratinocytes in psoriatic lesions. This study demonstrates that our engineered exosomes can not only act as a treat-to-target strategy for psoriasis treatment but also provide insight in clinical application of inflammatory disorders.

Ketone Bodies and Brain Metabolism: New Insights and Perspectives for Neurological Diseases.

Ketone Bodies and Brain Metabolism: New Insights and Perspectives for Neurological Diseases.

Effect of Coconut Oil Pulling on Plaque-Induced Gingivitis: A Prospective Clinical Study

Context: Oil pulling carried out with coconut oil plays a vital role in treating plaque, gingivitis and eradicating dental caries. Aims: The study was conducted to assess the effect of coconut oil pulling on plaque formation and plaque-related gingivitis. Settings and Design: A prospective clinical study was conducted at a Dental College and Hospital to assess the effect of coconut oil pulling on plaque formation and plaque-related gingivitis. Subjects and Methods: The study was conducted among 75 students, aged between 19 and 21 years. All the subjects were advised to perform oil pulling with 5 ml of edible coconut oil every morning for 5 min on empty stomach and before tooth brushing. The data for plaque and gingival index-scores were assessed periodically at baseline, 15th day, and 30th day. Statistical Analysis Used: The collected data were analyzed using student paired t-test with SPSS software version 22. Results: Among 75 enrolled patients, the reduction of means of Gingival Index scores at baseline was (1.178 ± 0.124), at 15th day was (1.076 ± 0.051) and at 30th day was (1.023 ± 0.020) and reduction of means of plaque Index scores at baseline was (1.518 ± 0.084), at 15th day was (1.257 ± 0.062) and at 30th day was (1.090 ± 0.054). A positive correlation between Gingival and Plaque Index scores was found between periods. The result for both was found to highly statistically significant, (P < 0.001). Conclusions: Coconut oil pulling when used as an adjunctive oral hygiene aid is effective in decreasing plaque formation and subsequent plaque-induced gingivitis.

Abstract 502: Trem2 Regulates Foamy Macrophage Formation In Atherosclerotic Plaque Formation

Atherosclerosis is driven by the accumulation of lipid in artery walls, leading to plaque formation. Plaque expansion is driven by monocyte infiltration where they differentiate into heterogeneous macrophage populations, including foamy macrophages. To understand genes that regulate monocyte differentiation toward foamy macrophages, we performed pseudotime analysis of murine scRNA-seq from atherosclerotic plaques. This analysis identified Trem2, a lipid sensor expressed on myeloid cells, as a potential regulator of foamy cell formation. These results were further supported by an in vitro genome-wide crispr screen performed on oxLDL-treated foamy macrophages, which identified Trem2 as a candidate regulator for oxLDL uptake. To test the role of macrophage Trem2 in atherosclerotic plaque formation, we generated Trem2 fl/fl CX3CR1 CreER LDLR -/- mice that delete Trem2 only in macrophages upon tamoxifen treatment (TAM). TAM enriched Western Diet (WD) feeding for 8 weeks lead to significantly decreased plaque formation in the aortic arch and aortic sinus of Trem-deficient mice compared to litermate control. Importantly, Trem2flox animals displayed comparable serum cholesterol levels to control mice following WD feeding. Finally, to determine whether Trem2 is required for foamy macrophage formation in vivo, we performed mixed bone marrow chimera of 50% Trem2 -/- marrow and 50% control marrow into Ldlr -/- recipients fed with western diet. Plaque associated Trem2-deficient macrophages failed to develop into foamy macrophages when in competition with WT macrophages, despite normal ratios of circulating monocytes. Overall, this data identifies Trem2 as a novel regulator of foamy macrophage formation and atherosclerotic plaque growth that could be targeted therapeutically to treat CVD.

Enhancement of Endothelial KCa Channel Activity as a Novel Strategy to Oppose Atherosclerosis

Atherosclerosis represents a major risk factor for cardiovascular disease and is associated with endothelial dysfunction (ED), which facilitates fatty plaque formation, impairs blood flow and increases arterial stiffness. A hallmark feature of ED is decreased bioavailability of nitric oxide (NO). We have previously reported that pharmacological activation of endothelial Ca2+‐activated K+ channels (KCa2.3 and KCa3.1) can oppose ED by enhancing endothelium‐dependent vasodilation.We hypothesized that improving endothelial function will mitigate the development and/or severity of atherosclerosis in Apoe knockout (Apoe‐/‐) mice. Administration of the KCa channel activator SKA‐31 was utilized to improve endothelial function in vivo.Experimentally, male, 8‐week old Apoe‐/‐ mice on a regular chow diet were administered one of three daily treatments for 16 weeks: SKA‐31 (10 mg/kg), the KCa3.1 channel blocker senicapoc (40 mg/kg), or drug vehicle alone. Pharmacological inhibition of KCa3.1 channels is reported to reduce atherosclerosis in Apoe‐/‐ mice and was utilized as a benchmark. Drugs were formulated in miglyol and condensed milk, which was readily ingested by the mice. Cardiac function and arterial pulse wave velocity (PWV) were assessed by echocardiography under isoflurane anesthesia. Atherosclerotic lesions in the aorta were visualized by Oil‐Red‐O staining and select tissue histology was carried out using H&E staining. Abdominal aortic contractility and relaxation were measured by wire myography in drug‐treated Apoe‐/‐ mice and age/sex‐matched wild‐type C57/BL6 mice.At the end of drug treatment, left ventricular (LV) ejection fraction, fractional shortening and LV posterior wall thickness were not different in Apoe‐/‐ mice treated with either SKA‐31 or senicapoc compared with vehicle. Measurements of aortic PWV showed no significant differences among the three groups, which indicated that neither drug treatment decreased aortic stiffness. Oil‐Red‐O staining of the thoracic aorta and aortic arch revealed fatty plaque formation in Apoe‐/‐ mice (i.e. 10‐12% of area) compared with WT controls (< 1%), however, neither SKA‐31 nor senicapoc treatments reduced plaque formation vs. vehicle. Phenylephrine (PE)‐evoked contraction of abdominal aortic rings appeared similar in WT and vehicle/drug treated Apoe‐/‐ mice, whereas endothelium‐dependent, acetylcholine‐induced relaxation of PE‐constricted aortic rings was enhanced in aortic rings from mice treated with SKA‐31 and senicapoc vs. vehicle. Although relaxation to the smooth muscle vasodilator sodium nitroprusside was augmented in Apoe‐/‐ mice compared with WT, this response was not altered by drug treatment.While both SKA‐31 and senicapoc improved aortic endothelial function, neither drug decreased plaque formation or aortic stiffness, perhaps due to the later onset of these events in the progression of atherosclerotic pathology. We will investigate this likelihood by feeding Apoe‐/‐ mice a high fat diet to accelerate the development of plaque formation and arterial stiffness to determine the effects of both drug treatments on these later stages of atherosclerosis.

Evaluation of Cocos nucifera and Sesamum indicum in comparison with Chlorhexidine on gingivitis - A double blind Clinico-Immunological study

Background: Myriad of synthetic products has been used in chemical plaque control. There is a constant search for cost effective herbal products with minimal adverse effect to substitute synthetic compounds. The objective of this study was to evaluate the anti-inflammatory properties of Cocos nucifera and Sesamum indicum and compare their effect with commercially available chlorhexidine on gingivitis. Methods: In this double blind, randomized, control clinical trial, a total of 45 samples from patients aged between 18 to 35 years reporting to the institution, diagnosed with gingivitis were selected and randomly divided into Group-A (Scaling + Cocos Nucifera mouthwash), Group-B (Scaling + Sesamum Indicum mouthwash) and Group C (Scaling + Chlorhexidine mouthwash). Clinical (Plaque index, Gingival index and Sulcus bleeding index), and Immunological (Interleukin-6) parameters were assessed at baseline and 45th day following scaling. Saliva samples were collected and stored at -200C till they were subjected to enzyme-linked immunosorbent assay (ELISA) analysis. Inferential statistics done were analysis of variance, paired t test, post hock Scheffe test and Chi- square test by using SPSS software (22.0). Results: In Clinical parameters, group B (p˂0.001) showed statistical significant reduction compared to group A and group C. In Immunological parameter group A (p˂0.001) showed statistical significant reduction in Interleukin-6 compared to group B and group C (p=0.126 & p=0.196 respectively). Conclusion: Cocos nucifera and Sesamum indicum mouth washes effectively decreased plaque formation and could be used as an adjunct to scaling in treating plaque induced gingivitis.

Apamin administration impact on miR-219 and miR-155-3p expression in cuprizone induced multiple sclerosis model.

Multiple sclerosis (MS) is a chronic debilitating disease that attacks the central nervous system. This study aims to investigate miR-219 and miR-155-3p expression levels involved in the myelination process following the administration of apamin peptide in the model of multiple sclerosis disease. Forty-four 8 week C57BL/6 male mice (22 ± 5 g) randomly divided into six groups. Apamin (100 µg/kg/BW) was administered intraperitoneally as a co-treatment during phase I (demyelination) or post-treatment phase II (remyelination) twice a week in cuprizone induced MS model. At the end of study myelin content and microRNA expression levels were measured with LFB staining and quantitative Real-Time PCR method, respectively. It was observed that the intended microRNAs were dysregulated during the different phases of disease induction. After 6 weeks of cuprizone exposure, miR-219 downregulated in phase I in comparison with the negative control. On the other hand, the apamin co-treatment significantly inhibit the miR-155-3p upregulation during the phase I as compared with the cuprizone group (p < 0.0001). Apamin has more impact on the miR155-3p reduction in phase I than miR-219 elevation in phase II. It could be considered as a therapeutic option for decreasing plaque formation during the exacerbation phase of the MS disease. Apamin has more impact on the miR155-3p reduction in phase I than miR-219 elevation in phase II. It could be considered as a therapeutic option for decreasing plaque formation during the exacerbation phase of the MS disease.

EFFECT OF KARAMUNTING LEAF EXTRACT (Melastoma malabathricum L.) ON GLUCOSYLTRANSFERASE ENZYME OF Streptococcus mutans

ABSTRACTBackground: Karamunting leaf extract has secondary metabolite compounds such as tannin, flavonoid, and phenol that have antibacteria potential to be used as an alternative to mouthwash in addition to Chlorhexidine 0.12% to lower the incidence of tooth caries. Caries is caused by several important virulence factors, including Streptococcus mutans Glucosyltransferase (GTF) enzyme. Karamunting leaf extract can inhibit the work of GTF enzyme by precipitating, denaturing protein and damaging cell walls. Inhibition of Streptococcus bacteria enzyme activity will decrease plaque formation, thus decreasing the potential of dental caries. Objective: The purpose of this study was to determine the effect of Karamunting leaf extract and 0,12% Chlorhexidine on Glucosyltransferase enzyme activity of Streptococcus mutans. Methods: This study used true experimental design with post test only with control group design using 7 groups, including Karamunting leaf extract group with 5%, 10%, 15%, 20%, and 25% concentrations to determine the activity of S. mutans GTF enzyme. Results: The results showed that Karamunting leaf extract with 20% concentration was able to decrease the activity of Glucosyltransferase enzyme in Streptococcus mutans. Conclusion: Karamunting leaf extract affects Streptococcus mutans Glucosyltransferase enzyme activity. Keywords: Chlorhexidine 0,12%, Glucosiltransferase, Melastoma malabathricum L., Streptococcus mutans.

Protective Activities of Dendrobium huoshanense C. Z. Tang et S. J. Cheng Polysaccharide against High-Cholesterol Diet-Induced Atherosclerosis in Zebrafish.

Cardiovascular disease is the highest cause of death, and atherosclerosis (AS) is the primary pathogenesis of many cardiovascular diseases. In this study, we aim to investigate the possible pharmaceutical effects of Dendrobium huoshanense C. Z. Tang et S. J. Cheng polysaccharide (DHP) in AS. We fed zebrafish with high-cholesterol diet (HCD) to establish a zebrafish AS model and treated with DHP and observed plaque formation and neutrophil counts under a fluorescence microscope. Next, a parallel flow chamber was utilized to establish low shear stress- (LSS-) induced endothelial cell (EC) dysfunction model. We observed that DHP significantly improved HCD-induced lipid deposition, oxidative stress, and inflammatory response, mainly showing that DHP significantly increased superoxide dismutase (SOD) activity, decreased plaque formation, and decreased neutrophil recruitment and the levels of total cholesterol (TC), triglyceride (TG), malondialdehyde (MDA), and reactive oxygen species (ROS). Furthermore, DHP significantly improved LSS-induced oxidative stress and EC dysfunction. Our results indicated that DHP can exert treatment effects on AS, which may attribute to its hypolipidemic, antioxidant, anti-inflammatory activities and improving LSS-induced EC dysfunction. DHP has promising potential for further development as a functional natural medicine source targeted at AS prevention.

Deletion of fibroblast activation protein provides atheroprotection.

Fibroblast activation protein (FAP) is upregulated at sites of tissue remodelling including chronic arthritis, solid tumours, and fibrotic hearts. It has also been associated with human coronary atherosclerotic plaques. Yet, the causal role of FAP in atherosclerosis remains unknown. To investigate the cause-effect relationship of endogenous FAP in atherogenesis, we assessed the effects of constitutive Fap deletion on plaque formation in atherosclerosis-prone apolipoprotein E (Apoe) or low-density lipoprotein receptor (Ldlr) knockout mice. Using en face analyses of thoraco-abdominal aortae and aortic sinus cross-sections, we demonstrate that Fap deficiency decreased plaque formation in two atherosclerotic mouse models (-46% in Apoe and -34% in Ldlr knockout mice). As a surrogate of plaque vulnerability fibrous cap thickness was used; it was increased in Fap-deficient mice, whereas Sirius red staining demonstrated that total collagen content remained unchanged. Using polarized light, atherosclerotic lesions from Fap-deficient mice displayed increased FAP targets in terms of enhanced collagen birefringence in plaques and increased pre-COL3A1 expression in aortic lysates. Analyses of the Stockholm Atherosclerosis Gene Expression data revealed that FAP expression was increased in human atherosclerotic compared to non-atherosclerotic arteries. Our data provide causal evidence that constitutive Fap deletion decreases progression of experimental atherosclerosis and increases features of plaque stability with decreased collagen breakdown. Thus, inhibition of FAP expression or activity may not only represent a promising therapeutic target in atherosclerosis but appears safe at the experimental level for FAP-targeted cancer therapies.